194例棘阿米巴角膜炎患者:不良结局与严重炎症并发症的危险因素
该研究回顾性审计了2000年7月至2012年4月Moorfields眼科医院的194例棘阿米巴角膜炎患者(194眼),其中93眼(48%)出现不良结局。多变量分析显示,不良结局与严重炎症并发症、年龄>34岁、使用抗阿米巴治疗前使用皮质类固醇及症状持续时间>37天独立相关;严重炎症并发症与年龄>34岁、抗阿米巴治疗前使用皮质类固醇及抗阿米巴治疗前曾按HSV角膜炎治疗独立相关。
要点
- 194眼中93眼(48%)出现不良结局。
- 不良结局的独立危险因素包括严重炎症并发症、年龄>34岁、抗阿米巴治疗前使用皮质类固醇及症状持续时间>37天。
- 严重炎症并发症的独立危险因素包括年龄>34岁、抗阿米巴治疗前使用皮质类固醇及抗阿米巴治疗前曾按HSV角膜炎治疗。
核心结论
- 及时诊断棘阿米巴角膜炎、避免误诊为HSV角膜炎以及在排除棘阿米巴角膜炎前避免使用皮质类固醇对获得良好结局和避免严重炎症并发症至关重要。
- 年龄较大是不可改变的危险因素,可能反映该患者亚群对棘阿米巴的免疫反应差异。
研究设计与样本
- 回顾性审计2000年7月至2012年4月Moorfields眼科医院棘阿米巴角膜炎病例的医疗记录,包括12例较早的手术病例,共纳入194眼(194例患者)。
- 不良结局定义为以下一项或多项:角膜穿孔、角膜移植术、其他手术(活检除外)、抗阿米巴治疗持续时间≥10.5个月(全队列第75百分位数)及最终视力≤20/80。
- 严重炎症并发症定义为巩膜炎和/或角膜基质环形浸润。
- 采用多变量分析识别不良结局和严重炎症并发症的独立危险因素。
主要发现
- 194眼中93眼(48%)出现不良结局。
- 不良结局与严重炎症并发症的存在、年龄>34岁、使用抗阿米巴治疗前使用皮质类固醇及抗阿米巴治疗前症状持续时间>37天相关。
- 严重炎症并发症的发生与年龄>34岁、使用抗阿米巴治疗前使用皮质类固醇及抗阿米巴治疗前曾按HSV角膜炎治疗独立相关。
关键数值与推荐
- 不良结局定义:角膜穿孔、角膜移植术、其他手术(活检除外)、抗阿米巴治疗持续时间≥10.5个月(全队列第75百分位数)或最终视力≤20/80中的一项或多项。
- 严重炎症并发症定义:巩膜炎和/或角膜基质环形浸润。
临床怎么用
- 及时诊断棘阿米巴角膜炎、避免误诊为HSV角膜炎以及在排除棘阿米巴角膜炎前避免使用皮质类固醇对获得良好结局和避免严重炎症并发症至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To determine demographic and clinical features of patients with Acanthamoeba keratitis (AK) that are independent risk factors both for bad outcomes and for severe inflammatory complications (SIC). METHODS: A retrospective audit of medical records of AK cases at Moorfields Eye Hospital from July 2000 to April 2012, including 12 earlier surgical cases. Cases with a bad outcome were defined as those having one or more of the following: corneal perforation, keratoplasty, other surgery (except biopsy), duration of antiamoebic therapy (AAT) ≥10.5 months (the 75th percentile of the whole cohort) and final visual acuity ≤20/80. SICs were defined as having scleritis and/or a stromal ring infiltrate. Multivariable analysis was used to identify independent risk factors for both bad outcomes and SICs. RESULTS: Records of 194 eyes (194 patients) were included, having bad outcomes in 93 (48%). Bad outcomes were associated with the presence of SIC, aged >34 years, corticosteroids used before giving AAT and symptom duration >37 days before AAT. The development of SIC was independently associated with aged >34 years, corticosteroids used before giving AAT and herpes simplex virus (HSV) keratitis treatment before AAT. CONCLUSIONS: The prompt diagnosis of AK, avoidance of a misdiagnosis of HSV keratitis and corticosteroid use before the exclusion of AK as a potential cause of keratitis are essential to the provision of a good outcome for patients and for the avoidance of SIC. Older age is an unmodifiable risk factor that may reflect differences in the immune response to AK in this patient subset.
引用
- Carnt N, Robaei D, Minassian DC, et al. Acanthamoeba keratitis in 194 patients: risk factors for bad outcomes and severe inflammatory complications. Br J Ophthalmol. 2018. PMID: 29298778. doi:10.1136/bjophthalmol-2017-310806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。